10 years in the making. And now, Europe. For a decade, AIM at Melanoma’s Women in Melanoma (WIM) initiative has…

In this conversation, we sit down with Amanda Goodstadt, Senior Staff Attorney at Triage Cancer, where she develops educational materials, leads…

August 19, 2026 6:45 am EDT First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in…

Thankfully, the third time was the charm! On August 6, 2026 the U.S. Food & Drug Administration (FDA) approved RP1…

Approval Offers New Hope for Patients with Anti-PD-1 Refractory Melanoma The following is the official press release issued by the…

AIM at Melanoma is proud to announce that our President, Samantha Guild, JD, has been selected as the recipient of…

August is the start of the back-to-school season across the U.S. so now is a good time to provide an…

What does advocacy really mean? For many people, advocacy means raising awareness. For us, it also means showing up where…

What does it mean to truly live well after a melanoma diagnosis? In this heartfelt episode of Beyond the Clinic:…

RP1 (vusolimogene oderparepvec ) in combination with nivolumab to treat advanced melanoma is being considered for approval by the FDA…